By Associate Professor Hao-Wen Sim

Journal articles

Donskov F; Xie W; Wells JC; Fraccon AP; Pasini F; Porta C; Stukalin I; Lee JL; Bamias A; Yuasa T; Davis ID; Pezaro C; Kanesvaran R; Bjarnason GA; Sim H-W; Agarwal N; Kollmannsberger CK; Canil CM; Choueiri TK; Heng DYC, 2017, 'Synchronous vs metachronous metastatic disease: Impact of time to metastasis on outcome in metastatic renal cell carcinoma patients treated with targeted therapy', Annals of Oncology, 28, pp. v311 - v312, http://dx.doi.org/10.1093/annonc/mdx371.037

Chan B; Sim H-W; Zimmermann C; Krzyzanowska MK, 2016, 'Systematic review of interventions to facilitate advance care planning (ACP) in cancer patients.', Journal of Clinical Oncology, 34, pp. 21 - 21, http://dx.doi.org/10.1200/jco.2016.34.26_suppl.21

Ruiz-Morales JM; Swierkowski M; Wells JC; Fraccon AP; Pasini F; Donskov F; Bjarnason GA; Lee JL; Sim HW; Sliwczynsk A; Ptak-Chmielewska A; Teter Z; Beuselinck B; Wood LA; Yuasa T; Pezaro C; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium', European Journal of Cancer, 65, pp. 102 - 108, http://dx.doi.org/10.1016/j.ejca.2016.06.016

Sim H-W; Zadeh G; Mason WP; Aldape K; Bernstein M; Gentili F; Hodaie M; Kalia S; Kongkham PN; Zhang W; Tung T; Chen EX, 2016, 'Comparison of oncometabolite 2-hydroxyglutarate (2HG) levels in mutant isocitrate dehydrogenase (IDH) versus wild-type (WT) glioma tissues.', Journal of Clinical Oncology, 34, pp. 2028 - 2028, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.2028

Ruiz Morales JM; Swierkowski M; Wells C; Fraccon AP; La Russa F; Donskov F; Bjarnason GA; Lee J-L; Sim H-W; Beuselinck B; Wood L; Yuasa T; Pezaro CJ; Rini BI; Szczylik C; Choueiri TK; Heng DYC, 2016, 'First-line sunitinib versus pazopanib in metastatic renal cell carcinoma (mRCC): Results from the international metastatic renal cell carcinoma database consortium (IMDC).', Journal of Clinical Oncology, 34, pp. 4510 - 4510, http://dx.doi.org/10.1200/jco.2016.34.15_suppl.4510

Li H; Kroeger N; de Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh HD; Rini BI; Knox JJ; Pantuck AJ; Choueiri TK; Heng DYC, 2016, 'The impact of active smoking on survival outcome in metastatic renal cell carcinoma patients treated with targeted therapy.', Journal of Clinical Oncology, 34, pp. 552 - 552, http://dx.doi.org/10.1200/jco.2016.34.2_suppl.552

Kröger N; Li H; De Velasco G; Donskov F; Sim H-W; Wells C; Stukalin I; Agarwal N; Parekh H; Rini B; Knox J; Pantuck A; Choueiri T; Heng D, 2016, '756 Active smoking is an adverse prognostic factor for survival outcome in metastatic renal cell carcinoma patients treated with targeted therapies', European Urology Supplements, 15, pp. e756 - e756, http://dx.doi.org/10.1016/s1569-9056(16)60758-3

Lalani A-K; Li H; Heng D; Wood L; Kalirai A; Bjarnason G; Sim H-W; Kollmannsberger CK; Kapoor A; Hotte SJ; Vanhuyse M; Czaykowski P; Reaume MN; Soulieres D; Venner P; North S; Basappa N, 2016, 'Real world outcomes of patients with metastatic renal cell carcinoma (mRCC) using first-line sunitinib or pazopanib: the Canadian experience', Annals of Oncology, 27, pp. vi285 - vi285, http://dx.doi.org/10.1093/annonc/mdw373.46

Tan LTY; Lewin JH; Urban D; Sim H-W; Hicks RJ; Byron K; Guccione L; Schaef E; Luen SJ; Tothill R; Schofield P; Bowtell D; Mileshkin LR, 2015, 'Retrospective review of the impact of a dedicated Cancer of Unknown Primary (CUP) clinic.', Journal of Clinical Oncology, 33, pp. e17680 - e17680, http://dx.doi.org/10.1200/jco.2015.33.15_suppl.e17680

Sim HW; Morris PG; Patil S; Khasraw M, 2014, 'Brain metastases in breast cancer', Expert Review of Anticancer Therapy, 14, pp. 173 - 183, http://dx.doi.org/10.1586/14737140.2014.863468

Conference Papers

Sim HW; Wachsmuth L; Barnes EH; Yip S; Koh ES; Hall M; Jennens R; Ashley DM; Verhaak RG; Heimberger AB; Rosenthal MA; Hovey EJ; Ellingson BM; Tognela A; Gan HK; Wheeler H; Back M; Mcdonald KL; Long A; Cuff K; Begbie S; Gedye C; Mislang A; Le H; Johnson MO; Kong BY; Simes JR; Lwin Z; Khasraw M, 2023, 'NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma', in Neuro-Oncology Advances, http://dx.doi.org/10.1093/noajnl/vdad124

Haider S; Dai E; Sim H; Balakrishnar B; Descallar J; Ding P; Chua W, 2020, 'Systematic review and meta-analysis of treatment related toxicities from second-generation androgen receptor inhibitors in advanced prostate cancer', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY, pp. 121 - 121, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000790145400145&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Sim H-W; Barnes E; Lwin Z; Rosenthal M; Wheeler H; Koh E-S; Foote MC; Fisher L; Leonard R; Hall M; Simes J; Khasraw M, 2019, 'Health-related quality of life (HRQL) in VERTU: A randomized phase II trial of veliparib (V), radiotherapy (RT), and temozolomide (TMZ) for newly diagnosed MGMT unmethylated (uMGMT) glioblastoma (GBM).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2042

Xu K; Lo A; Chin V; Gzell C; O'Connor C; Forstner D; Gallagher R; Bova R; Crawford J; Harvey R; Lochhead A; Earls P; Qiu MR; Hsu E; Bigg-Wither G; Chan L; Bao H; Foltyn P; Sim HW; Prawira A, 2018, 'Development of overall survival (OS) and progression free survival (PFS) nomograms for Australian patients with locoregionally advanced oropharyngeal squamous cell carcinoma (LA OPSCC)', in Annals of oncology : official journal of the European Society for Medical Oncology, pp. viii389, http://dx.doi.org/10.1093/annonc/mdy287.049

Conference Abstracts

Klingberg D; Bae S; Zhou D; Sim H-W; Cai R; Anazodo A; Grimison PS; Lewis CR; Lee YC, 2022, 'Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.', in Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO), Vol. 40, pp. 11570 - 11570, http://dx.doi.org/10.1200/jco.2022.40.16_suppl.11570

Sim HW; Mcdonald KL; Lwin Z; Barnes EH; Rosenthal M; Foote MC; Koh ES; Back M; Wheeler H; Sulman EP; Buckland ME; Fisher L; Leonard R; Hall M; Ashley DM; Yip S; Simes J; Khasraw M, 2021, 'A randomized phase II trial of veliparib, radiotherapy, and temozolomide in patients with unmethylated MGMT glioblastoma: The VERTU study', in Neuro-Oncology, Vol. 23, pp. 1736 - 1749, http://dx.doi.org/10.1093/neuonc/noab111

Khasraw M; McDonald KL; Rosenthal M; Lwin Z; Ashley DM; Wheeler H; Barnes E; Foote MC; Koh E-S; Sulman EP; Back M; Buckland M; Sim H-W; Fisher L; Leonard R; Hall M; Yip S; Simes J, 2019, 'A randomized phase II trial of veliparib (V), radiotherapy (RT) and temozolomide (TMZ) in patients (pts) with unmethylated MGMT (uMGMT) glioblastoma (GBM).', in JOURNAL OF CLINICAL ONCOLOGY, AMER SOC CLINICAL ONCOLOGY, IL, Chicago, Vol. 37, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 31 May 2019 - 04 June 2019, http://dx.doi.org/10.1200/JCO.2019.37.15_suppl.2011

Preprints

Hallal S; Azimi A; Wei H; Ho N; Lee M; Sim H-W; Sy J; Shivalingam B; Buckland ME; Kaufman KL, 2020, A comprehensive proteomic SWATH-MS workflow for profiling blood extracellular vesicles: a new avenue for glioma tumour surveillance, http://dx.doi.org/10.1101/2020.03.05.979716

Other

Sim H-W; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX, 2023, Data from Tissue 2-Hydroxyglutarate as a Biomarker for <i>Isocitrate Dehydrogenase</i> Mutations in Gliomas, http://dx.doi.org/10.1158/1078-0432.c.6528165.v1

Sim H-W; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX, 2023, Data from Tissue 2-Hydroxyglutarate as a Biomarker for <i>Isocitrate Dehydrogenase</i> Mutations in Gliomas, http://dx.doi.org/10.1158/1078-0432.c.6528165

Sim H-W; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX, 2023, Supplementary materials from Tissue 2-Hydroxyglutarate as a Biomarker for <i>Isocitrate Dehydrogenase</i> Mutations in Gliomas, http://dx.doi.org/10.1158/1078-0432.22472232

Sim H-W; Nejad R; Zhang W; Nassiri F; Mason W; Aldape KD; Zadeh G; Chen EX, 2023, Supplementary materials from Tissue 2-Hydroxyglutarate as a Biomarker for <i>Isocitrate Dehydrogenase</i> Mutations in Gliomas, http://dx.doi.org/10.1158/1078-0432.22472232.v1

Back to profile page